【摘要】 目的 分析血清微RNA(miR)-1290在胰腺癌患者中的表达水平及与临床病理的关系，以探讨miR-1290和CA19-9联合检测在胰腺癌中的诊断价值。方法 通过3个独立的GEO数据集分析，筛选出胰腺癌患者血清中表达上调的miR-1290,采用实时荧光定量聚合酶链反应(real-time fluorescence quantitative polymerase chain reaction, RT-qPCR)检测35例胰腺癌患者、23例胰腺良性疾病患者和20例健康志愿者血清miR-1290的表达水平，分析其与临床病理特征之间的相关性。采用受试者操作特征(receiver operator characteristic, ROC)曲线对血清miRNA、CA19-9、miRNA联合CA19-9检测的诊断价值比较。结果 通过GEO数据集分析发现，miR-1290在胰腺癌患者中表达上调。胰腺癌患者血清miR-1290水平[0.51(0.37,0.85)]显著高于胰腺良性疾病组[0.14(0.05,0.28)]及健康对照组[0.08(0.04,0.22)],差异均有统计学意义(P<0.05)。miR-1290联合CA19-9检测对区分胰腺癌组与胰腺良性疾病组(AUC为0.929、敏感度为85.7%、特异性为87.0%)、胰腺癌组与健康对照组(AUC为0.959、敏感度为91.4%、特异性为85.0%)、胰腺癌组与所有对照组(AUC为0.942、敏感度为85.7%、特异性为90.7%)优于任一单一指标。胰腺癌患者血清miR-1290表达水平与肿瘤T分期、是否存在淋巴结转移及远处转移有关(P<0.05),miR-1290高表达是影响胰腺癌发生的危险因素。结论 胰腺癌患者血清miR-1290表达升高，与胰腺癌的发生、发展相关，可作为胰腺癌诊断的生物学标志物。联合检测miR-1290和CA19-9诊断胰腺癌价值优于任一单一指标。更多还原

【Abstract】 Objective To analyze the expression of serum micro RNA(miR)-1290 in patients with pancreatic cancer and its relationship with clinicopathological, and explore the diagnostic value of combined detection of miR-1290 and CA19-9 in pancreatic cancer. Methods The up-regulated miR-1290 expression in the serum of pancreatic cancer patients was screened by three independent GEO data sets. The expression of miR-1290 in serum was determined by real-time fluorescence quantitative polymerase chain reaction(RT-qPCR) among 35 pancreatic cancer patients, 23 benign disease patients and 20healthy controls. and analyze its correlation with clinicopathological features of pancreatic cancer patients. The diagnostic value of serum miRNA, CA19-9 and miRNA combined with CA19-9 were compared by receiver operator characteristic curve(ROC) for. Results Through GEO data set analysis, the expression of miR-1290 was up-regulated in pancreatic cancer patients. The level of serum miR-1290 in pancreatic cancer patients [0.51(0.37, 0.85)]was significantly higher than that in benign disease patients [0.14(0.05, 0.28)] and healthy controls [0.08(0.04, 0.22)], the differences were statistically significant(P<0.05). miR-1290 combined with CA19-9 was better than any single index in distinguish pancreatic cancer patients from benign disease patients(AUC was 0.929, sensitivity was 85.7%, specificity was 87.0%), pancreatic cancer patients from healthy controls(AUC was 0.959, sensitivity was 91.4%, specificity was 85.0%), pancreatic cancer patients from all controls(AUC was 0.942, sensitivity was 85.7%, specificity was 90.7%). The expression level of serum miR-1290 in patients with pancreatic cancer was correlated with T stage, lymph node metastasis and distant metastasis(P<0.05), and the high expression of miR-1290 was a risk factor affecting the occurrence of pancreatic cancer. Conclusion Serum miR-1290 expression was elevated in patients with pancreatic cancer. It is associated with the occurrence and development of pancreatic cancer. It can be used as a biomarker in the diagnosis of pancreatic cancer. The diagnosis value of miR-1290 combined with CA19-9 in of pancreatic cancer is superior to that of any single indicator更多还原